Clocinnamox

Clocinnamox (CCAM or C-CAM; developmental code name NIH-10443) is a selective and irreversible antagonist of the μ-opioid receptor. Closely related compounds include methocinnamox (MCAM) and methoclocinnamox (MCCAM). They were derived via structural modification of buprenorphine. Clocinnamox was first described in the scientific literature by 1992.
Wikipedia contributors, "Clocinnamox", Wikipedia, revision 1380590246, retrieved 20 November 2026, source, CC BY-SA 4.0.